Pre-made Daclizumab benchmark antibody ( Whole mAb, anti-IL2RA therapeutic antibody, Anti-CD25/IDDM10/IL2R/IMD41/TCGFR/p55 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-129

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-129 Category Tag

Product Details

Pre-Made Daclizumab biosimilar, Whole mAb, Anti-IL2RA Antibody: Anti-CD25/IDDM10/IL2R/IMD41/TCGFR/p55 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Daclizumab (trade name Zinbryta) is a therapeutic humanized monoclonal antibody which was used for the treatment of adults with relapsing forms of multiple sclerosis (MS). Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T-cells.

Products Name (INN Index)

Pre-Made Daclizumab biosimilar, Whole mAb, Anti-IL2RA Antibody: Anti-CD25/IDDM10/IL2R/IMD41/TCGFR/p55 therapeutic antibody

INN Name

Daclizumab

Target

IL2RA

Format

Whole mAb

Derivation

Humanized

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Approved

Est. Status

Active

100% SI Structure

3nfs:HL/3nfp:HL:AB

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

1994

Companies

AbbVie,Biogen,Dana-Farber Cancer Institute,National Cancer Institute (USA),PDL BioPharma

Conditions Approved

Renal transplant rejection

Conditions Active

Multiple sclerosis

Conditions Discontinued

Asthma,Graft-versus-host disease,Haematological malignancies,Immune-mediated uveitis,Liver transplant rejection,Psoriasis,Tropical spastic paraparesis,Type 1 diabetes mellitus,Ulcerative colitis

Development Tech

GS Gene Expression System

Previous Name

NA

Gm Offical Target Name

IL2RA

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide